An answer. Families had waited, often for years, without knowing why.
In the Aosta Valley of northwestern Italy, a team of researchers has offered 29 families something rare and quietly transformative: a reason. By sequencing the complete genomes of 110 children with autism and intellectual disabilities alongside their parents, scientists have begun converting diagnostic silence into molecular clarity — not a cure, but a map where there was once only uncertainty. The study, the first of its kind conducted entirely in Italy, also uncovered previously unknown disease-associated genes, suggesting that the catalog of what we know about the human mind's development is still being written.
- For families of children with autism or intellectual disabilities, years of unanswered 'why' have made the search for a genetic explanation feel both urgent and exhausting.
- Sifting through 26 million genetic variants required AI-assisted filtering just to separate meaningful signals from the vast noise of the human genome.
- Twenty-nine families received a concrete genetic diagnosis — not a treatment, but an explanation that reshapes how doctors can plan care and how families can understand their child's future.
- A mutation in the KALRN gene, found in one patient with autism and motor difficulties, has now been flagged as a likely contributor to neurodevelopmental disease — a gene hiding in plain sight until now.
- Patients who were tested years ago, before these genes were understood, may now be eligible for reassessment, extending the study's reach far beyond its original 110 participants.
In the foothills of northwestern Italy, researchers from the Italian Institute of Technology and the Aosta Valley regional health authority set out to answer one of medicine's most persistent questions: why do some children develop autism, intellectual disabilities, or both? By sequencing the complete genomes of 110 children and their parents — 300 individuals in total — they went looking for the genetic variants that had, until now, remained invisible. For 29 families, the search produced answers.
Neurodevelopmental disorders affect roughly one in a hundred Italian children between ages seven and nine, yet they remain stubbornly difficult to diagnose. Symptoms vary enormously from child to child, and the molecular roots of those differences are rarely visible without deep genomic investigation. The study, published in npj Genomic Medicine and the first of its kind conducted entirely in Italy, enrolled three groups: children with autism alone, those with intellectual disability alone, and those carrying both diagnoses simultaneously.
The sequencing generated approximately 26 million genetic variants. Using AI algorithms trained to recognize patterns in genes already linked to neurodevelopmental function, the team filtered that vast data down to meaningful findings. In 29 cases, they identified a clear genetic cause — and with it, something families had often waited years to receive: an explanation. Dr. Laure Obino, who leads the regional child neuropsychiatry unit, described the significance plainly: a genetic diagnosis does not cure a condition, but it ends the search, informs care decisions, and allows families to plan.
The study also reached beyond those 29 families. Researchers identified a mutation in the KALRN gene — central to how neurons develop and connect — in a patient with autism and motor difficulties, marking it as a newly implicated disease gene. Patients who underwent genetic testing years ago, when fewer genes were understood, may now be candidates for reassessment. Stefano Gustincich of the Italian Institute of Technology described the broader ambition: healthcare that is more personalized, more predictive, and more faithfully matched to each child's actual biology. A child's genetic makeup, once a mystery, is slowly becoming a map.
In the foothills of northwestern Italy, researchers have begun untangling one of medicine's most persistent puzzles: why some children develop autism, intellectual disabilities, or both, and what in their DNA might explain it. A team working across the Italian Institute of Technology and the regional health authority in Aosta Valley sequenced the complete genomes of 110 children and their parents, hunting for the genetic variants that could account for conditions that had, until now, remained diagnostically silent. For 29 families, the search yielded answers.
Neurodevelopmental disorders are common enough to matter. In Italy, roughly one child in a hundred between ages seven and nine carries a diagnosis—autism spectrum disorder, intellectual disability, or some combination of both. Yet these conditions remain stubbornly difficult to pin down. Symptoms shift from person to person. A child might display high-functioning autism with few additional complications, or might struggle with both social interaction and cognitive tasks that most children manage without thought. The variability makes diagnosis hard and treatment harder still. Molecular investigation—looking directly at the genome—offers a way forward, but only if researchers know what to look for.
The study, published in npj Genomic Medicine and the first of its kind conducted entirely in Italy, began in May 2022 as part of a larger initiative called 5000genomi@VdA. The researchers assembled three groups of participants to capture the full spectrum of neurodevelopmental complexity. Forty young people had autism spectrum disorder without additional disabilities, most displaying the profile associated with high-functioning autism. Twenty-seven had been diagnosed with intellectual disability alone, facing real obstacles in managing daily life independently. The remainder carried diagnoses of both conditions simultaneously—the compounded challenge of social and cognitive impairment.
When the team analyzed the complete genomes of these 110 children and their parents—300 individuals in total—the data was staggering: approximately 26 million genetic variants emerged from the sequencing. The real work lay in filtering signal from noise. Using artificial intelligence algorithms designed to recognize patterns in genes already known to influence neurodevelopmental function, the researchers began to isolate variants that might actually matter. In 29 cases, they found it: a clear genetic diagnosis, a variant or set of variants that could account for the child's condition, and information about how the mutation had been inherited.
For the families involved, this represented something that had been missing: an answer. Dr. Laure Obino, who directs the child neuropsychiatry unit at the regional health authority, described the weight of that finding. Families had waited, often for years, without knowing why their child was different. A genetic diagnosis does not cure the condition, but it does something nearly as valuable—it explains it. It allows doctors to make more informed decisions about care. It lets families understand what to expect and how to plan. It ends the exhausting search for an explanation.
Beyond the 29 families who received diagnoses, the study uncovered something else: genes that had never before been linked to neurodevelopmental disorders at all. In one patient with autism and motor difficulties, researchers identified a mutation in the KALRN gene, which plays a central role in how neurons develop and connect to one another. This single finding suggests the gene should be added to the growing catalog of those implicated in neurodevelopmental disease. As more patients are sequenced, more such discoveries will likely emerge—genes that have been hiding in plain sight, their role in these conditions only now becoming visible.
The implications ripple outward. Patients who underwent genetic testing years ago, when fewer genes were understood, might now be reassessed with new knowledge. Future diagnoses can be made with greater precision. Medicine becomes less generic and more tailored to the individual child's actual biology. Stefano Gustincich, who directs the genomics center at the Italian Institute of Technology, framed it as a shift toward healthcare that is more personalized, more predictive, and more aligned with what patients actually need. It is a modest but real step toward a future where a child's genetic makeup is not a mystery but a map.
Notable Quotes
We were able to provide long-awaited answers to many families by identifying the genetic cause of their condition, which can help inform care decisions and follow-up planning.— Dr. Laure Obino, director of child neuropsychiatry at Azienda USL della Valle d'Aosta
This collaboration demonstrates the impact that advanced genomics can have in clinical practice, helping make health care more personalized, predictive and better aligned with patients' needs.— Stefano Gustincich, director of the Center for Clinical and Computational Genomics at IIT in Aosta
The Hearth Conversation Another angle on the story
Why does it matter that this study happened in Italy specifically, rather than somewhere else?
Italy hadn't done a whole-genome study like this before. There's a gap between what's possible and what's actually been done in different countries. This closes that gap for Italian families and Italian clinicians. It also means the data reflects the genetic diversity of that population—which matters because genetic variants aren't evenly distributed across ancestry groups.
You mentioned 29 families got answers. What about the other 81?
That's the hard part. The study didn't fail for those families—it just means their genetic cause wasn't found yet. Maybe the variant is in a gene no one has connected to these disorders. Maybe it's a type of mutation the current algorithms don't catch. But now those families' data exists. As knowledge grows, some of them might get answers retroactively.
The KALRN gene discovery—is that a breakthrough?
It's a signal, not a breakthrough yet. One patient with a KALRN mutation doesn't prove the gene causes autism. But it's enough to say: look here. Other researchers will now sequence more patients and see if KALRN mutations appear again. If they do, the gene moves from "interesting finding" to "established risk factor."
Does a genetic diagnosis change how you treat the condition?
Not directly. You can't cure autism by knowing its genetic cause. But you can make better decisions. You know what to monitor for. You can counsel families about recurrence risk. You can connect them to support groups for people with the same genetic variant. And you stop the family from chasing dead ends—the endless testing, the wondering if something else might be wrong.
What happens to this data now?
It becomes part of the scientific commons. Other researchers can access it, study it, build on it. The 26 million variants they identified—those are now catalogued. As more people are sequenced globally, patterns will emerge that weren't visible in 110 families. That's how science accelerates.